{"entity":{"id":"fc-effector","kind":"term","name":"Fc engineering / effector function","aka":[],"tldr":"Tweaking the antibody's tail to make it recruit immune cells more strongly, or not at all.","summary":"Fc engineering means tweaking the antibody's tail, the Fc region, so that it recruits immune cells more strongly, or not at all. Afucosylation and Fc mutations enhance ADCC, whereas Fc-silencing through an IgG4 backbone or LALA mutations prevents unwanted immune activation in checkpoint inhibitors and T-cell engagers, and FcRn-binding mutations extend half-life. The term is linked to the Monoclonal antibodies and Bispecific antibodies technologies and to the terms Antibody, NK cell and Half-life. It is cited by the drug records for Margetuximab, Tislelizumab and Mogamulizumab, by the pathways on myeloid suppression, complement in cancer and NK-cell recognition, and by an idea on bispecific antibodies that engage macrophages instead of T cells.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Fragment_crystallizable_region","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Fragment_crystallizable_region"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["monoclonal-antibody","bispecific-antibody"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Immunology"},"route":"/terms/fc-effector/","neighbours":{"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"margetuximab","kind":"drug","name":"Margetuximab","route":"/drugs/margetuximab/"},{"id":"mogamulizumab","kind":"drug","name":"Mogamulizumab","route":"/drugs/mogamulizumab/"},{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"idea":[{"id":"idea-bio2-myeloid-engager-bispecific","kind":"idea","name":"Bispecific antibodies that engage macrophages instead of T cells","route":"/ideas/idea-bio2-myeloid-engager-bispecific/"}],"term":[{"id":"antibody","kind":"term","name":"Antibody","route":"/terms/antibody/"},{"id":"half-life","kind":"term","name":"Half-life","route":"/terms/half-life/"},{"id":"nk-cell","kind":"term","name":"NK cell","route":"/terms/nk-cell/"}],"institution":[{"id":"southampton-cancer","kind":"institution","name":"University Hospital Southampton / Centre for Cancer Immunology","route":"/institutions/southampton-cancer/"}],"pathway":[{"id":"complement-in-cancer","kind":"pathway","name":"Complement in cancer","route":"/pathways/complement-in-cancer/"},{"id":"myeloid-suppression-axis","kind":"pathway","name":"Myeloid suppression: TAMs, MDSCs & don't-eat-me signals","route":"/pathways/myeloid-suppression-axis/"},{"id":"nk-cell-recognition","kind":"pathway","name":"NK-cell recognition: missing self & stress ligands","route":"/pathways/nk-cell-recognition/"}]}}